Dextromethorphan-Quinidine in Treatment-Resistant Depression: An Open-Label Pilot Study

被引：0
|
作者：
Wang, Philip [1 ]
Yavi, Mani [1 ]
Park, Lawrence [1 ]
Zarate, Carlos [1 ]
机构：
[1] NIMH, Bethesda, MD 20892 USA
来源：
BIOLOGICAL PSYCHIATRY | 2023年 / 93卷 / 09期
基金：
美国国家卫生研究院;
关键词：
Clinical Trials; NMDA antagonists; Treatment Resistant Depression; Psychopharmacological Treatment; Dextromethorphan;
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
208
引用
收藏
页码：S177 / S178
页数：2
相关论文
共 50 条
  • [21] Lithium versus lamotrigine augmentation in treatment resistant unipolar depression: a randomized, open-label study
    Schindler, Frank
    Anghelescu, Ion G.
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2007, 22 (03) : 179 - 182
  • [22] Efficacy and Safety of Intranasal Esketamine in Patients With Treatment-Resistant Depression and Comorbid Chronic Post-traumatic Stress Disorder: Open-Label Single-Arm Pilot Study
    Rotharmel, Maud
    Benosman, Cherifa
    El-Hage, Wissam
    Berjamin, Caroline
    Ribayrol, Diane
    Guillin, Olivier
    Gaillard, Raphael
    Berkovitch, Lucie
    Moulier, Virginie
    FRONTIERS IN PSYCHIATRY, 2022, 13
  • [23] An open-label study to assess safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in dementia: PRISM II results
    Doody, Rachelle S.
    D'Amico, Stephen
    Cutler, Andrew J.
    Davis, Charles S.
    Shin, Paul
    Ledon, Fred
    Yonan, Charles
    Siffert, Joao
    CNS SPECTRUMS, 2016, 21 (06) : 450 - 459
  • [24] Dextromethorphan/quinidine pharmacotherapy in patients with treatment resistant depression: A proof of concept clinical trial
    Murrough, James W.
    Wade, Elizabeth
    Sayed, Sehrish
    Ahle, Gabriella
    Kiraly, Drew D.
    Welch, Alison
    Collins, Katherine A.
    Soleimani, Laili
    Iosifescu, Dan V.
    Charney, Dennis S.
    JOURNAL OF AFFECTIVE DISORDERS, 2017, 218 : 277 - 283
  • [25] A Pilot Study: An Open-Label Biomarker Development of Ketamine for Unipolar Refractory Depression
    Kang, Melody J. Y.
    Vazquez, Gustavo
    BIOLOGICAL PSYCHIATRY, 2021, 89 (09) : S92 - S93
  • [26] Intranasal Esketamine in Treatment-resistant Depression, a Dose Response Study - Double Blind and Open Label Extension Data
    Daly, Ella
    Singh, Jaskaran
    Fedgchin, Maggie
    Cooper, Kimberly
    Lim, Pilar
    Melman, Caroline
    Manji, Husseini
    Van Nueten, Luc
    Shelton, Richard
    Thase, Michael
    Ahmad, Maha
    deBruecker, Geert
    Drevets, Wayne
    NEUROPSYCHOPHARMACOLOGY, 2015, 40 : S340 - S341
  • [27] Pramipexole for stage 2 treatment-resistant major depression: An open study
    Inoue, Takeshi
    Kitaichi, Yuji
    Masui, Takuya
    Nakagawa, Shin
    Boku, Shuken
    Tanaka, Teruaki
    Suzuki, Katsuji
    Nakato, Yasuya
    Usui, Reiko
    Koyama, Tsukasa
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2010, 34 (08) : 1446 - 1449
  • [28] Open Label Psilocybin Administration in Severely Treatment Resistant Depression
    Aaronson, Scott
    Miller, Tammy
    Rudow, Samuel
    Forbes, MacKenzie
    Suppes, Trisha
    BIOLOGICAL PSYCHIATRY, 2022, 91 (09) : S244 - S244
  • [29] Dextromethorphan/Quinidine Combination as a Novel Pharmacotherapeutic Approach in Patients With Treatment Resistant Depression: A Proof of Concept Clinical Trial
    Murrough, James
    Wade, Elizabeth
    Sayed, Seharish
    Ahle, Gabby
    Kiraly, Drew
    Welch, Alison
    Collins, Katherine
    Soleimani, Laili
    Iosifescu, Dan
    Charney, Dennis
    NEUROPSYCHOPHARMACOLOGY, 2016, 41 : S504 - S505
  • [30] Baseline monocyte count predicts symptom improvement during intravenous ketamine therapy in treatment-resistant depression: a single-arm open-label observational study
    Pedraz-Petrozzi, Bruno
    Spangemacher, Moritz
    Deicher, Anton
    Drews, Lena
    Defert, Julie
    Silva-Colmenero, Ana Yaiza
    Wein, Paul
    Riedinger, Elena
    Gruender, Gerhard
    Gilles, Maria
    Sartorius, Alexander
    Reinwald, Jonathan R.
    FRONTIERS IN PSYCHIATRY, 2024, 15
12345